Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

Accenture PLC (ACN) is expected to report $3.32 for 3Q. CarMax Inc (KMX) is expected to report $1.19 for 1Q. Coffee Holding Co Inc (JVA) is expected to report $0.06 for 2Q. Darden Restaurants Inc (DRI ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Fintel reports that on June 18, 2025, LifeSci Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

Asian shares are mixed and oil prices have advanced after the escalation of conflict in the Middle East hit Wall Street.

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

NEW YORK (AP) — U.S. stocks are nudging lower on Tuesday, and oil prices are rising again. It’s a modest return to form for financial markets after worries had seemed to calm on Wall Street Monday.

U.S. stocks slumped under the weight of a jump for the price of oil. The S&P 500 fell 0.8% Tuesday following signals that ...